WordNet

of or relating to or resembling papilla (同)papillose
a flexible cap on a babys feeding bottle or pacifier
the small projection of a mammary gland (同)mammilla, mamilla, pap, teat, tit
(botany) a tiny outgrowth on the surface of a petal or leaf
a small nipple-shaped protuberance concerned with taste, touch, or smell; "the papillae of the tongue"
a small projection of tissue at the base of a hair or tooth or feather

PrepTutorEJDIC

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/03/06 21:29:06」(JST)

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 甲状腺乳頭癌の概要 overview of papillary thyroid cancer
2. 分化型甲状腺癌：マネージメントの概要 differentiated thyroid cancer overview of management
3. 悪性腹膜中皮腫：治療 malignant peritoneal mesothelioma treatment
4. 上皮性卵巣癌、卵管癌、および腹膜癌：疫学および危険因子 epithelial carcinoma of the ovary fallopian tube and peritoneum epidemiology and risk factors
5. 色素沈着過剰を有する患者へのアプローチ approach to the patient with hyperpigmentation disorders

Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.

Matsuse M, Mitsutake N, Tanimura S, Ogi T, Nishihara E, Hirokawa M, Fuziwara CS, Saenko VA, Suzuki K, Miyauchi A, Yamashita S.SourceDepartment of Radiation Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
International journal of cancer. Journal international du cancer.Int J Cancer.2013 Feb 1;132(3):738-43. doi: 10.1002/ijc.27709. Epub 2012 Jul 21.
An activating mutation in the BRAF gene is the most common genetic alteration in papillary thyroid carcinomas (PTCs). The mutation in PTCs is almost a c.1799T>A transversion, resulting in a p.V600E amino acid substitution (BRAF(V600E) ). Here, we report a novel complex BRAF mutation identified in
PMID 22752848

CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.

Ke CC, Liu RS, Yang AH, Liu CS, Chi CW, Tseng LM, Tsai YF, Ho JH, Lee CH, Lee OK.SourceInstitute of Clinical Medicine, National Yang Ming University, Taipei, 11221, Taiwan.
European journal of nuclear medicine and molecular imaging.Eur J Nucl Med Mol Imaging.2013 Jan;40(1):61-71. doi: 10.1007/s00259-012-2242-5. Epub 2012 Oct 19.
PURPOSE: (131)I therapy is regularly used following surgery as a part of thyroid cancer management. Despite an overall relatively good prognosis, recurrent or metastatic thyroid cancer is not rare. CD133-expressing cells have been shown to mark thyroid cancer stem cells that possess the characterist
PMID 23081821